{"id":54684,"date":"2026-04-30T07:10:00","date_gmt":"2026-04-30T00:10:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=54684"},"modified":"2026-04-30T07:10:00","modified_gmt":"2026-04-30T00:10:00","slug":"ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=54684","title":{"rendered":"Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span>, April 30, 2026<\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today poster presentations highlighting multiple programs at the American Diabetes Association’s (ADA’s) 2026 Scientific Sessions, taking place June 5\u20138, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an\u00a0eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity.<\/p>\n

\n<\/div>\n

Presentation details<\/b><\/p>\n

Title: <\/b>ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity<\/p>\n

Session:<\/b> Late Breaking Poster Session (3067-LB)<\/p>\n

Date\/Time:<\/b> Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Title:<\/b> Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity<\/p>\n

Session:<\/b> Sunday General Poster Session (1672-P)<\/p>\n

Date\/Time:<\/b> Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Title:<\/b> ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies<\/p>\n

Session:<\/b> Sunday General Poster Session (1673-P)<\/p>\n

Date\/Time:\u00a0<\/b>Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Additional information about the ADA’s 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association<\/a>).<\/p>\n

About Ascletis Pharma Inc.<\/b><\/p>\n

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R\/GIPR dual peptide agonist and ASC37, a GLP-1R\/GIPR\/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n

For more information, please visit www.ascletis.com<\/a>.<\/p>\n

Contact:<\/p>\n

Peter\u00a0Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a><\/p>\n

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span>, April 30, 2026<\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today poster presentations highlighting multiple programs at the American Diabetes Association’s (ADA’s) 2026 Scientific Sessions, taking place June 5\u20138, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an\u00a0eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity.<\/p>\n

\n<\/div>\n

Presentation details<\/b><\/p>\n

Title: <\/b>ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity<\/p>\n

Session:<\/b> Late Breaking Poster Session (3067-LB)<\/p>\n

Date\/Time:<\/b> Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Title:<\/b> Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity<\/p>\n

Session:<\/b> Sunday General Poster Session (1672-P)<\/p>\n

Date\/Time:<\/b> Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Title:<\/b> ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies<\/p>\n

Session:<\/b> Sunday General Poster Session (1673-P)<\/p>\n

Date\/Time:\u00a0<\/b>Sunday, June 7, 2026, 12:30 PM CT<\/p>\n

Additional information about the ADA’s 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association<\/a>).<\/p>\n

About Ascletis Pharma Inc.<\/b><\/p>\n

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R\/GIPR dual peptide agonist and ASC37, a GLP-1R\/GIPR\/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n

For more information, please visit www.ascletis.com<\/a>.<\/p>\n

Contact:<\/p>\n

Peter\u00a0Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a><\/p>\n

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-54684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54684"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54684\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}